Anti-inflammatory activity of erycristagallin, a pterocarpene from Erythrina mildbraedii.
Erycristagallin, a pterocarpene isolated from Erythrina mildbraedii, was tested in vitro for its antioxidant properties on the stable 2,2-diphenyl-1-pycryl-hydrazyl (DPPH) free radical and on the arachidonic acid metabolism. In addition, erycristagallin was tested on different experimental models of inflammation, such as the acute and chronic inflammation induced by the application of 12-O-tetradecanoylphorbol 13-acetate (TPA) on mice and the phospholipase A(2)-induced mouse paw oedema test. In the carrageenan-induced mouse paw oedema test, the ethyl acetate extract obtained from E. mildbraedii showed anti-inflammatory activity, and erycristagallin was isolated as the active principle. In vivo, erycristagallin significantly inhibited the phospholipase A(2)-induced mouse paw oedema as well as the mouse ear oedema induced by TPA (ID(50)<10 microg/ear). Moreover, it significantly reduced the chronic inflammation and leukocyte infiltration induced by repeated application of TPA. In vitro, erycristagallin inhibited the arachidonic acid metabolism via the 5-lipoxygenase pathway in rat polymorphonuclear leukocytes (IC(50)=23.4 microM), but had no effect on cyclooxygenase-1 metabolism in human platelets, while showing antioxidant activity in the DPPH test. As with other phenolics, the anti-inflammatory activity of erycristagallin may be based on its capacity to inhibit the arachidonic acid metabolism via the 5-lipoxygenase pathway.
Njamen
Dieudonné
D
Laboratory of Animal Physiology, Department of Animal Biology and Physiology, Faculty of Science, University of Yaounde 1, P.O. Box 812, Yaounde, Cameroon.
Talla
Emmanuel
E
Mbafor
Joseph Tanyi
JT
Fomum
Zacharias Tanee
ZT
Kamanyi
Albert
A
Mbanya
Jean-Claude
JC
Cerdá-Nicolás
Miguel
M
Giner
Rosa M
RM
Recio
M Carmen
MC
Ríos
José Luis
JL
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology*; D000975:Antioxidants / Q000302:isolation & purification / Q000494:pharmacology*; D016718:Arachidonic Acid / Q000378:metabolism; D001713:Biphenyl Compounds; D002351:Carrageenan; D004423:Ear / Q000473:pathology; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D004895:Erythrina / Q000737:chemistry*; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology; D006576:Heterocyclic Compounds, 4 or More Rings; D006614:Hindlimb / Q000473:pathology; D007529:Isoflavones / Q000302:isolation & purification / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000378:metabolism; D051379:Mice; D010741:Phospholipases A; D010851:Picrates / Q000378:metabolism; D010936:Plant Extracts / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D001713:Biphenyl Compounds; D016166:Free Radical Scavengers; D006576:Heterocyclic Compounds, 4 or More Rings; D007529:Isoflavones; D010851:Picrates; D010936:Plant Extracts; C477693:erycristagallin; D007975:Leukotriene B4; D016718:Arachidonic Acid; D002351:Carrageenan; C004931:1,1-diphenyl-2-picrylhydrazyl; D010741:Phospholipases A